[Edaily Reporter Kwon Oh Seok ] The KOSPI remains stuck in a downward trend due to selling by foreign investors. The KOSPI and KOSDAQ indices are displayed on a screen in the Hana Bank dealing room in Seoul on the 7th. (Photo = Yonhap News) According to MP Doctor on the 7th, the KOSPI opened at 6,864.25, down 77.14 points (1.11%) from the previous trading day, and as of 1:46 p.m., it was trading at 6,866.89, down 74.50 points (1.07%), hovering around the 6,800 level. So far, retail investors are the only group showing net buying, at 1.6903 trillion won, while foreign and institutional investors are net sellers at 1.7620 trillion won and 496.3 billion won, respectively. By trading type, combined arbitrage and non-arbitrage trades show a net selling position of 1.4697 trillion won. Leading semiconductor stocks are also unable to escape the downward trend. Today, SamsungElectronics(005930)is trading at 271,750 won, down 250 won (0.09%), while SK hynix(000660)is trading at 1,739,000 won, down 34,000 won (1.92%). This is believed to be due to caution ahead of SamsungElectronics’ earnings announcement and concerns over an AI (artificial intelligence) bubble, both of which are affecting investor sentiment. The KOSDAQ index opened at 917.45, down 2.47 points (0.27%) from the previous trading day, and is currently trading at 904.83, down 15.09 points (1.64%) at the same time. In the KOSDAQ market as well, retail investors are the only group showing net buying, at 449.5 billion won, while foreign and institutional investors are net sellers at 302.6 billion won and 120.0 billion won, respectively. By trading type, combined arbitrage and non-arbitrage trades show a net selling position of 296.5 billion won.
SAMSUNG BIOLOGICS(207940)has announced plans to respond strictly, in accordance with the law and established principles, to any illegal or unlawful acts related to the conflict with the labor union ov…
“‘Jjarur,’ a jajangmyeon-flavored instant noodle made with lard, sold 10 million servings within 100 days of its launch. The company aims to surpass 10 billion won in sales by the end of the year.” (K…
NeoImmuneTech, Inc.(950220)announced on the 7th that its U.S. partner, Tolerance Bio, presented “NT-I7” (epineptakin alfa), a long-acting interleukin-7 (IL-7) candidate, as a key clinical pipeline for…